These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 36249660)

  • 1. Comparison of the Warfarin Dosing and Outcomes in Hmong Versus East Asians Patients: Real-World Data From an Integrated Healthcare System.
    Sun B; Yew PY; Wen YF; Chi CL; Straka RJ
    Cureus; 2022 Sep; 14(9):e28905. PubMed ID: 36249660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in Predicted Warfarin Dosing Requirements Between Hmong and East Asians Using Genotype-Based Dosing Algorithms.
    Sun B; Wen YF; Culhane-Pera KA; Lo M; Xiong T; Lee K; Peng K; Thyagarajan B; Bishop JR; Zierhut H; Straka RJ
    Pharmacotherapy; 2021 Mar; 41(3):265-276. PubMed ID: 33202062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations.
    Wen YF; Culhane-Pera KA; Thyagarajan B; Bishop JR; Zierhut H; Lo M; Xiong T; Peng K; Holzer K; Lee K; Straka RJ
    Pharmacotherapy; 2020 Feb; 40(2):142-152. PubMed ID: 31884695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomic variabilities in geo-ancestral subpopulations and their clinical implications: Results of collaborations with Hmong in the United States.
    Sun B; Wen YF; Culhane-Pera KA; Lo M; Straka RJ
    Front Genet; 2022; 13():1070236. PubMed ID: 36685861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
    Stergiopoulos K; Brown DL
    JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study.
    Kwon S; Lee SR; Choi EK; Choe WS; Lee E; Jung JH; Han KD; Oh S; Lip GYH
    Am Heart J; 2020 Nov; 229():81-91. PubMed ID: 32927313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.
    Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Anderson JL; Li J; Rodriguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple B; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
    JAMA; 2019 Sep; 322(9):834-842. PubMed ID: 31479138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
    Lin D; Chen Y; Yong J; Wu S; Zhou Y; Li W; Tan X; Liu R
    Front Cardiovasc Med; 2021; 8():768730. PubMed ID: 34901228
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal loading dose of warfarin for the initiation of oral anticoagulation.
    Mahtani KR; Heneghan CJ; Nunan D; Bankhead C; Keeling D; Ward AM; Harrison SE; Roberts NW; Hobbs FD; Perera R
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD008685. PubMed ID: 23235665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Identification of Novel
    Wen YF; Gaedigk A; Boone EC; Wang WY; Straka RJ
    Front Pharmacol; 2022; 13():867331. PubMed ID: 35387332
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Impact of Setting a Narrow International Normalized Ratio Target Range in the Management of Older Adult Patients on Warfarin.
    Ong PY; Koomanan N; Cheen MH; Lai YF; Lim SH; Kong MC; Ng HJ
    Clin Appl Thromb Hemost; 2016 Sep; 22(6):528-34. PubMed ID: 26239317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.
    Dietz N; Ruff C; Giugliano RP; Mercuri MF; Antman EM
    Int J Cardiol; 2020 Oct; 317():159-166. PubMed ID: 32505370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.